The effects observed from cells with different levels of STX18 might hint at novel strategy to exploit cell cycle checkpoint deficiency for enhancing the efficacy of radiotherapy in NSCLC and simultaneously suppressing its metastatic potential. The gene discussed is STX18; the disease is non-small cell lung carcinoma.